The survival rate for one type of cancer afflicting young patients chronic myelocytic leukemia has increased from 0% in the early 1980s to 75%.

FORBES: Removing "Dismal" From Dismal Median Household Income Statistics

In results from a late-stage trial released in August, Vidaza was shown to have increased the survival of patients with a high-risk type of MDS from 15 months to 24 months.

FORBES: Magazine Article

Being of a familiar type did not guarantee a male success and survival, but it brought pretty good odds with it.

ECONOMIST: Female spiders are picky lovers